TICKERNERD
Menu
MIRMMIRMHealthcare · Biotechnology

MIRM Stock Forecast: Mirum Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 2 Oct 2026
$83
−1.18% on the day

The 14 Wall Street analysts covering Mirum Pharmaceuticals, Inc. hold a median 12-month price target of $139 — +67.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 66 of 100 as at 3 Oct 2026 — in the upper half.

Market cap
$5.4B
Ticker Nerd rank
66 / 100
Median analyst target
$139
Analysts covering
14
Revenue$176.2M+37.9% y/y
Operating income−$26.1M
Net income−$67.2M
Free cash flow−$69.3M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−7.5%
1M
−16.9%
YTD
+5.0%
1Y
+15.6%
From 52W high
−35.5%
From 52W low
+29.4%
$64
$129
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

MIRM stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Mirum Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 3 Oct 2026
66 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
91
Value
80
Revisions
79
Momentum
78
Accruals
69
Quality
61
Growth
39
Size
22
Issuance
7

Volatility (91): The share price has been relatively steady.

Issuance (7): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

MIRM stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on MIRM, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$50$100$150$200Jan 26Apr 26Jul 26Oct 26MIRMHigh $195Median $139Low $118

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says14 analysts
14 Buy0 Hold0 Sell
Low $118Median $139High $195

The green dot is the last close — the median target sits +67.0% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 5 moved their price target up and 4 moved it down.

DateFirmActionRatingTarget
29 Sept 2026BairdMaintainsOutperform$123 → $130
29 Sept 2026CitigroupMaintainsBuy$145 → $160
28 Sept 2026HC Wainwright & Co.MaintainsBuy$140 → $195
27 Aug 2026CitizensReiteratesMarket Outperform—
27 Aug 2026CitizensReiteratesMarket Outperform$137
6 Aug 2026CitizensMaintainsMarket Outperform—
6 Aug 2026CitizensMaintainsMarket Outperform$146 → $137
6 Aug 2026HC Wainwright & Co.MaintainsBuy$185 → $140
6 Aug 2026HC Wainwright & Co.MaintainsBuy—
6 Aug 2026RBC CapitalMaintainsOutperform—
6 Aug 2026RBC CapitalMaintainsOutperform$148 → $135
6 Aug 2026TD CowenMaintainsBuy—
6 Aug 2026TD CowenMaintainsBuy$145 → $140
7 July 2026RBC CapitalMaintainsOutperform—
7 July 2026RBC CapitalMaintainsOutperform$142 → $148
2 July 2026JP MorganMaintainsOverweight—
2 July 2026JP MorganMaintainsOverweight$115 → $125
15 June 2026CitizensMaintainsMarket Outperform—
11 June 2026Morgan StanleyMaintainsOverweight—
2 June 2026CitigroupInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. MIRM appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

MIRM vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 2 Oct 2026, Mirum Pharmaceuticals, Inc. returned +15.6% against +16.2% for the S&P 500, dividends included.

MIRM vs S&P 500, last 12 monthsTotal return, rebased to 100
80100120140160180Jan 26Apr 26Jul 26Oct 26MIRMS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

MIRM analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

Mirum Pharmaceuticals, Inc. (MIRM) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−176.4×

Cheaper than 99% of US stocks

Price / sales
8.7×

Cheaper than 16% of US stocks

Price / book
−504.3×

Cheaper than 99% of US stocks

EV / EBITDA
−81.2×

Cheaper than 96% of US stocks

Growth & margins
Revenue growth (YoY)
37.9%

Higher than 82% of US stocks

Earnings growth (YoY)
37.9%

Higher than 70% of US stocks

Gross margin
82.8%

Higher than 93% of US stocks

Operating margin
−14.8%

Higher than 23% of US stocks

Net margin
−139.2%

Higher than 4% of US stocks

Returns & dividend
Return on equity
−703.0%

Higher than 2% of US stocks

Return on assets
−6.8%

Higher than 30% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Mirum Pharmaceuticals, Inc. (MIRM) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Mirum Pharmaceuticals, Inc. has a market value of $5.4B and an enterprise value of $5.7B.

  • Revenue in the twelve months to 30 June 2026: $618.1M. The latest quarter grew 37.9% year on year.

  • Net income over the same four quarters: −$860.2M, a −139.2% net margin.

  • Diluted earnings per share, trailing twelve months: $−14.55.

  • Free cash flow in the twelve months to 30 June 2026: −$263.7M.

  • Shares outstanding: 64.8M.

  • Trailing P/E: −176.4×; forward P/E: −239.2× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Mirum Pharmaceuticals, Inc. employs 433 people — $1.4M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 5 Oct 2026

Data provided by Twelve Data

Peers

MIRM vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
MIRMMirum Pharmaceuticals, Inc.$5.4B
66
TVTXTravere Therapeutics, Inc.$5.4B
86
CRSPCRISPR Therapeutics AG$5.3B
37
COGTCogent Biosciences, Inc.$5.3B
34
PTCTPTC Therapeutics, Inc.$5.3B
64
ORKAOruka Therapeutics, Inc.$5.6B
40
KODKodiak Sciences, Inc.$5.7B
49

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Mirum Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest MIRM news & analysis

Mirum Pharmaceuticals' Brevlovitug Hits Phase III Endpoint in Hepatitis Delta Study

MarketBeat · 2 Oct 2026positive

Mirum Pharmaceuticals reported positive top-line results from the Phase III portion of its AZURE-1 study of brelovitug for chronic hepatitis delta. The investigational antibody met its primary endpoint at 24 weeks and demonstrated a favorable tolerability profile.

Why it matters — A MIRM watcher would care because this positive Phase III data advances brelovitug's development for chronic hepatitis delta, potentially expanding the company's pipeline.

Mirum's Brelovitug Meets Goal in Phase III AZURE-1 Study in HDV

Zacks Investment Research · 29 Sept 2026positive

Mirum Pharmaceuticals announced that its drug brelovitug met its primary goal in the Phase III AZURE-1 study for chronic hepatitis delta virus (HDV). The trial showed strong virologic response and ALT normalization rates.

Why it matters — A positive Phase III outcome for brelovitug advances Mirum's pipeline and could support a potential regulatory path for a new HDV treatment.

Mirum Pharmaceuticals, Inc. (MIRM) Discusses Topline Results from Phase III AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Transcript

Seeking Alpha · 28 Sept 2026neutral

Mirum Pharmaceuticals discussed topline results from its Phase III AZURE-1 study of brelovitug in chronic hepatitis delta, as covered in a Seeking Alpha transcript. The item reports on the company's presentation of these study findings.

Why it matters — Phase III results for a key investigational therapy are a significant data point for MIRM watchers following the company's hepatitis delta pipeline.

MIRM Secures FDA Nod for an Ultra-Rare Bone Disorder Therapy

Zacks Investment Research · 28 Sept 2026positive

Mirum Pharmaceuticals received FDA approval for Atebrioz to treat fibrodysplasia ossificans progressiva (FOP), an ultra-rare bone disorder. The approval was supported by PROGRESS data showing a reduction in new heterotopic ossification lesion volume.

Why it matters — A MIRM watcher would care because the FDA approval expands Mirum's commercial portfolio into a new ultra-rare disease therapy, adding a potential growth driver beyond its existing products.

Mirum's liver infection drug lowers virus levels in late-stage study

Reuters · 28 Sept 2026positive

Mirum Pharmaceuticals announced that its experimental hepatitis drug reduced virus levels in patients, meeting the primary goal of a late-stage study.

Why it matters — This positive late-stage result for Mirum's liver infection drug could be a significant milestone for the company's pipeline.

FAQ

Frequently asked questions about MIRM stock

What is the MIRM stock price forecast for 2026-2027?

The 14 Wall Street analysts covering Mirum Pharmaceuticals, Inc. have a median 12-month price target of $139, with estimates ranging from $118 to $195. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is MIRM stock a buy right now?

Of the 14 analysts covering Mirum Pharmaceuticals, Inc., 14 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Mirum Pharmaceuticals, Inc. 66 out of 100 across roughly 4,600 US stocks as at 3 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank MIRM?

As at 3 Oct 2026, Mirum Pharmaceuticals, Inc. ranks 66 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (91 of 100).

Will MIRM stock go up?

No one can know that. What the data says: the median 12-month target from 14 analysts implies +67.0% from the last close, and Ticker Nerd's factor model ranks Mirum Pharmaceuticals, Inc. 66 out of 100 as at 3 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the MIRM stock forecast for 2030?

No analyst covering Mirum Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MIRM are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $118 to $195 over the next 12 months.

How has MIRM stock performed over the past year?

Mirum Pharmaceuticals, Inc. returned +15.6% over the 12 months to 2 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Mirum Pharmaceuticals, Inc. do?

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company focused on rare and orphan diseases, with particular strength in liver and bile-acid related disorders.

What is the latest news on MIRM?

The most recent item we track (MarketBeat, 2 Oct 2026): "Mirum Pharmaceuticals' Brevlovitug Hits Phase III Endpoint in Hepatitis Delta Study". Mirum Pharmaceuticals reported positive top-line results from the Phase III portion of its AZURE-1 study of brelovitug for chronic hepatitis delta. The investigational antibody met its primary endpoint at 24 weeks and demonstrated a favorable tolerability profile.

Company

About Mirum Pharmaceuticals, Inc.

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company focused on rare and orphan diseases, with particular strength in liver and bile-acid related disorders. The company develops and commercializes approved medicines and investigational therapies designed for patients with serious conditions that have limited treatment options. Its commercial portfolio includes treatments for Alagille syndrome, progressive familial intrahepatic cholestasis, bile-acid synthesis disorders, and cerebrotendinous xanthomatosis, supported by a pipeline of additional rare-disease programs. Mirum operates as a specialty rare-disease company, combining drug development, regulatory expertise, and patient-support capabilities to serve children, adults, and families affected by complex genetic and metabolic conditions. Headquartered in Foster City, California, Mirum Pharmaceuticals plays a focused role in the global rare-disease market by bringing targeted therapies to highly specialized clinical settings.

CEO Mr. Christopher Peetz · 433 employees · United States · https://www.mirumpharma.com